dc.contributor.author | Ni, Guoying | |
dc.contributor.author | Wang, Tianfang | |
dc.contributor.author | Yang, Lin | |
dc.contributor.author | Wang, Yuejian | |
dc.contributor.author | Liu, Xiaosong | |
dc.contributor.author | Wei, Ming Q | |
dc.date.accessioned | 2018-09-11T03:51:10Z | |
dc.date.available | 2018-09-11T03:51:10Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 2164-5515 | |
dc.identifier.doi | 10.1080/21645515.2015.1089008 | |
dc.identifier.uri | http://hdl.handle.net/10072/123750 | |
dc.description.abstract | Late stage solid tumors cause significant cancer mortality rates worldwide and effective therapy remains a big challenge. Cancer therapeutic vaccines elicit tumor specific T cells that kill tumor cells yet often fail to result in tumor destruction because of the limited T cell response and the local immune-suppressive environment. Blocking interleukin 10 (IL-10) signaling at the time of therapeutic vaccination elicits much stronger T cell responses than vaccination without IL-10 blocking. Anaerobic oncolytic bacteria target hypoxic regions of the late stage tumor tissues which not only stops tumor growth but also provides a pro-inflammatory environment that may increase the effectiveness of a therapeutic vaccine by recruiting more effector T cells to tumor site. In this review, we argue that combining both bacterial and vaccine therapies may improve the efficiency of late stage cancer management. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Taylor & Francis | |
dc.relation.ispartofpagefrom | 599 | |
dc.relation.ispartofpageto | 606 | |
dc.relation.ispartofissue | 3 | |
dc.relation.ispartofjournal | Human Vaccines & Immunotherapeutics | |
dc.relation.ispartofvolume | 12 | |
dc.subject.fieldofresearch | Immunology | |
dc.subject.fieldofresearch | Medical microbiology | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences not elsewhere classified | |
dc.subject.fieldofresearchcode | 3204 | |
dc.subject.fieldofresearchcode | 3207 | |
dc.subject.fieldofresearchcode | 3214 | |
dc.subject.fieldofresearchcode | 321499 | |
dc.title | Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.faculty | Griffith Health, School of Medical Science | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Wei, Ming Q. | |